Curis, Inc.
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4…